Department of Pharmacy, University Hospital Virgen del Rocío, Seville, Spain.
Clinical Unit of Infectious Diseases, Clinical Microbiology and Parasitology. Institute of Biomedicine of Seville/Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain.
Front Immunol. 2024 Aug 29;15:1447926. doi: 10.3389/fimmu.2024.1447926. eCollection 2024.
Despite effective antiretroviral therapy (ART), 15-30% of people with HIV experience poor CD4 T-cell recovery, termed immunologic non-responders (INR). This study aims to evaluate whether pre-ART plasma levels of interleukin-6 (IL-6), interferon gamma-induced protein-10 (IP-10), macrophage inflammatory protein-1-β (MIP-1β), and/or pentraxin-3 (PTX-3) could predict subsequent immunologic recovery. Seventy-four participants were enrolled and classified as INR and immunologic responders (IR) based on CD4/CD8 ratio increase over 24 months after starting ART. The results showed no significant differences in cytokine levels between INR and IR. Therefore, IL-6, IP-10, MIP-1β, and PTX-3 were unsuitable as predictive markers of poor immune recovery.
尽管采用了有效的抗逆转录病毒疗法(ART),仍有 15-30%的 HIV 感染者存在 CD4 T 细胞恢复不良的情况,称为免疫无应答者(INR)。本研究旨在评估 ART 前血浆中白细胞介素-6(IL-6)、干扰素γ诱导蛋白-10(IP-10)、巨噬细胞炎症蛋白-1-β(MIP-1β)和/或五聚素-3(PTX-3)的水平是否可以预测随后的免疫恢复情况。本研究共纳入了 74 名参与者,并根据开始 ART 后 24 个月内 CD4/CD8 比值的增加情况将其分为 INR 和免疫应答者(IR)。结果显示,INR 和 IR 之间细胞因子水平没有显著差异。因此,IL-6、IP-10、MIP-1β 和 PTX-3 不适合作为免疫恢复不良的预测标志物。